The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Chemours Co director Alister Cowan purchased 13,000 shares of Chemours common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.62 per share, with individual trade prices ranging from $15.58 to $15.62. Following this purchase, Cowan’s directly owned holdings, including restricted stock units and dividend equivalent units, total 56,988.0387 shares.
Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share. Following this purchase, she reports beneficial ownership of 113,140.9469 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President of Thermal & Specialized Solutions, reported a purchase of 1,939.8014 shares of common stock on August 7, 2026 at $15.47 per share in an open-market or private transaction. Following this transaction, his reported direct holdings total 55,431.4012 shares, which include directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co Chief Financial Officer Shane Hostetter purchased common stock in a personal transaction. On 2026-08-06, he bought 3,350 shares of Chemours common stock at $14.94 per share. Following this purchase, he directly and beneficially owned a total of 102,697.7058 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co Chief Financial Officer Shane Hostetter reported a disposition of 3,087 shares of common stock on 2026-08-06. According to the disclosure, these shares were automatically withheld to satisfy tax obligations upon vesting of restricted stock units and related dividend equivalent units, and no shares were sold. Following this tax-withholding transaction, Hostetter directly holds a total of 99,347.7058 shares, including common shares, restricted stock units, and dividend equivalent units.
The Chemours Company reported Q2 2026 net sales of $1.591 billion and a net loss attributable to Chemours of $274 million, or $1.81 per basic and diluted share. For the first six months of 2026, net sales were $2.972 billion and the net loss was $303 million.
Thermal & Specialized Solutions generated $591 million of Q2 net sales and Titanium Technologies $661 million. Operating cash flow for the first half of 2026 was $114 million, while purchases of property, plant, and equipment totaled $93 million.
At June 30, 2026, Chemours reported total assets of $7.150 billion, total current liabilities of $1.861 billion, long‑term debt of $3.838 billion and total Chemours stockholders’ equity of $(49) million. The company held $671 million of unrestricted cash and had $953 million available under its revolving credit facility, and stated it believes it has sufficient liquidity to timely settle its current liabilities through at least the end of August 2027, although adverse outcomes in legal or environmental matters could have a material adverse effect on liquidity. Chemours also revised certain 2025 figures for immaterial errors primarily related to the timing of income tax expense recognition.
The Chemours Company reported Q2 2026 results with net sales of $1.59 billion, down 1% year over year, and a net loss of $274 million ($1.81 per share), narrower than a $380 million loss a year earlier. Adjusted net income was $64 million and Adjusted EBITDA $247 million, both below prior‑year levels.
Free cash flows rose to $114 million from $50 million, lifting the free cash flow conversion rate to 46% and contributing to a net leverage ratio of 4.4x on a trailing twelve‑month Adjusted EBITDA basis. Consolidated gross debt was $3.9 billion and total liquidity was $1.6 billion, including $671 million of unrestricted cash and $953 million of revolver capacity.
Thermal & Specialized Solutions delivered $591 million of sales and a 36% Adjusted EBITDA margin, aided by pricing despite softer Opteon™ aftermarket demand. Titanium Technologies saw modest sales and EBITDA gains from TiO2 price increases, while Advanced Performance Materials experienced lower sales and a 48% EBITDA decline, offset by strong growth in Performance Solutions serving data center and semiconductor markets.
Results reflected significant litigation and environmental charges related to PFAS matters and settlements, partly offset by a gain on Kuan Yin land sales. For full‑year 2026, Chemours projects 1–5% net sales growth, $775–$825 million Adjusted EBITDA, free cash flow conversion above 25%, and a net leverage ratio of around 3.8x by year‑end.
Chemours Co reports that President, Advanced Performance Materials, Familiar Calderon Gerardo had 943 shares of common stock automatically withheld on August 1, 2026 to satisfy tax obligations on vesting restricted stock units and dividend equivalent units.
No shares were sold in the market, and holdings after the withholding were 58,498.8899 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President, Thermal & Specialized Solutions, had 663 shares of common stock automatically withheld on 2026-08-01 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state this was a tax-withholding disposition and that no shares were sold. After this event, Martinko holds a total of 54,818.5559 shares, including directly owned shares, restricted stock units and dividend equivalent units.
Chemours Co director and Chief Executive Officer Denise Dignam reported a tax-withholding disposition of 477 shares of common stock on August 1, 2026 at $16.61 per share. Shares were automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; no shares were sold. Following this withholding, she reported 337,492.9016 shares held directly, including restricted stock units and dividend equivalent units.